and sedation.gabapentin enacarbilMonitor Closely (1)gabapentin enacarbil, trazodone. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.galantamineMinor (1)galantamine increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.ganaxoloneMonitor Closely (1)trazodone and ganaxolone both increase sedation. Use Caution/Monitor.gemifloxacinSerious - Use Alternative (1)gemifloxacin and trazodone both increase QTc interval. Avoid or Use Alternate Drug.gemtuzumabMonitor Closely (1)trazodone and gemtuzumab both increase QTc interval. Use Caution/Monitor.gentamicinMonitor Closely (1)trazodone will decrease the level or effect of gentamicin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.gilteritinibSerious - Use Alternative (1)gilteritinib and trazodone both increase QTc interval. Avoid or Use Alternate Drug.glasdegibSerious - Use Alternative (1)trazodone and glasdegib both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, monitor for increased risk of QTc interval prolongation.glimepirideMinor (1)trazodone increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown.glipizideMinor (1)trazodone increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown.glyburideMinor (1)trazodone increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown.glycopyrrolateMinor (1)glycopyrrolate and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.glycopyrrolate inhaledMinor (2)glycopyrrolate inhaled and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown. trazodone increases levels of glycopyrrolate inhaled by unknown mechanism. Minor/Significance Unknown.goserelinMonitor Closely (1)goserelin increases toxicity of trazodone by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.granisetronSerious - Use Alternative (1)granisetron and trazodone both increase QTc interval. Avoid or Use Alternate Drug.grapefruitMonitor Closely (1)grapefruit will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.green teaMonitor Closely (1)green tea, trazodone. Other (see comment). Use Caution/Monitor. Comment: Combination may increase risk of bleeding.griseofulvinMonitor Closely (1)griseofulvin will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.guanfacineSerious - Use Alternative (1)trazodone decreases effects of guanfacine by Other (see comment). Avoid or Use Alternate Drug. Comment: Inhibition of uptake by adrenergic neurons.haloperidolMonitor Closely (1)haloperidol and trazodone both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)trazodone and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.henbaneMonitor Closely (1)henbane and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.histrelinMonitor Closely (1)histrelin increases toxicity of trazodone by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.homatropineMonitor Closely (1)homatropine and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.huperzine AMonitor Closely (1)huperzine A increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.hydrocodoneMonitor Closely (1)hydrocodone, trazodone. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.hydrocortisoneMonitor Closely (2)hydrocortisone will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. trazodone will decrease the level or effect of hydrocortisone by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.hydromorphoneMonitor Closely (1)hydromorphone and trazodone both increase sedation. Use Caution/Monitor.hydroxyprogesterone caproate (DSC)Minor (1)hydroxyprogesterone caproate (DSC), trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.hydroxyzineMonitor Closely (1)hydroxyzine and trazodone both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)hydroxyzine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.hyoscyamineMonitor Closely (1)hyoscyamine and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.hyoscyamine sprayMonitor Closely (1)hyoscyamine spray and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.ibuprofenMonitor Closely (1)trazodone, ibuprofen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.ibuprofen IVMonitor Closely (1)trazodone, ibuprofen IV. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.ibutilideContraindicated (1)trazodone and ibutilide both increase QTc interval. Contraindicated.idelalisibSerious - Use Alternative (1)idelalisib will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substratesiloperidoneMonitor Closely (3)trazodone and iloperidone both increase QTc interval. Modify Therapy/Monitor Closely. iloperidone and trazodone both increase sedation. Use Caution/Monitor. iloperidone increases levels of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.imatinibMonitor Closely (1)trazodone will decrease the level or effect of imatinib by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.imipramineMonitor Closely (2)imipramine and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor. imipramine and trazodone both increase sedation. Use Caution/Monitor.Serious - Use Alternative (2)imipramine and trazodone both increase QTc interval. Avoid or Use Alternate Drug. trazodone and imipramine both increase serotonin levels. Avoid or Use Alternate Drug.indapamideContraindicated (1)trazodone and indapamide both increase QTc interval. Contraindicated.indinavirMonitor Closely (2)trazodone will decrease the level or effect of indinavir by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. indinavir will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.indomethacinMonitor Closely (1)trazodone, indomethacin. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.inotuzumabSerious - Use Alternative (1)inotuzumab and trazodone both increase QTc interval. Avoid or Use Alternate Drug. If unable to avoid concomitant use, obtain ECGs and electrolytes before and after initiation of any drug known to prolong QTc, and periodically monitor as clinically indicated during treatment.insulin aspartMinor (1)trazodone increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.insulin detemirMinor (1)trazodone increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown.insulin glargineMinor (1)trazodone increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown.insulin glulisineMinor (1)trazodone increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown.insulin lisproMinor (1)trazodone increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown.insulin NPHMinor (1)trazodone increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown.insulin regular humanMinor (1)trazodone increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown.ipratropiumMonitor Closely (1)ipratropium and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.irinotecan liposomalMonitor Closely (1)trazodone will decrease the level or effect of irinotecan liposomal by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.isavuconazonium sulfateMonitor Closely (1)trazodone will increase the level or effect of isavuconazonium sulfate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.isocarboxazidContraindicated (1)isocarboxazid and trazodone both increase serotonin levels. Contraindicated.isofluraneSerious - Use Alternative (1)isoflurane and trazodone both increase QTc interval. Avoid or Use Alternate Drug.isoniazidMonitor Closely (2)isoniazid will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. trazodone and isoniazid both increase serotonin levels. Modify Therapy/Monitor Closely.isoproterenolMonitor Closely (1)trazodone increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)trazodone, isoproterenol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.Minor (1)isoproterenol, trazodone. Mechanism: unknown. Minor/Significance Unknown. Risk of cardiac arrhythmias.istradefyllineMonitor Closely (1)istradefylline will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates.itraconazoleMonitor Closely (1)trazodone will decrease the level or effect of itraconazole by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.Serious - Use Alternative (2)trazodone and itraconazole both increase QTc interval. Avoid or Use Alternate Drug. itraconazole will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.ivermectinMonitor Closely (1)trazodone will decrease the level or effect of ivermectin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.ivosidenibSerious - Use Alternative (1)ivosidenib will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP3A4 substrates with ivosidenib or replace with alternative therapies. If coadministration is unavoidable, monitor patients for loss of therapeutic effect of these drugs.ketamineMonitor Closely (1)ketamine and trazodone both increase sedation. Use Caution/Monitor.Minor (1)ketamine, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.ketoconazoleSerious - Use Alternative (2)trazodone and ketoconazole both increase QTc interval. Avoid or Use Alternate Drug. ketoconazole will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.ketoprofenMonitor Closely (1)trazodone, ketoprofen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.ketorolacMonitor Closely (1)trazodone, ketorolac. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.ketorolac intranasalMonitor Closely (1)trazodone, ketorolac intranasal. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.ketotifen, ophthalmicMonitor Closely (1)trazodone and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.L-tryptophanMonitor Closely (1)trazodone and L-tryptophan both increase serotonin levels. Modify Therapy/Monitor Closely.lapatinibMonitor Closely (3)trazodone will decrease the level or effect of lapatinib by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. trazodone and lapatinib both increase QTc interval. Modify Therapy/Monitor Closely. lapatinib will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.larotrectinibMinor (1)larotrectinib will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.lasmiditanMonitor Closely (1)lasmiditan, trazodone. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.lefamulinContraindicated (1)lefamulin will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lefamulin is contraindicated with CYP3A substrates know to prolong the QT interval.lemborexantMonitor Closely (1)trazodone will increase the level or effect of lemborexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Lower nightly dose of lemborexant recommended if coadministered with weak CYP3A4 inhibitors. See drug monograph for specific dosage modification.lenacapavirMonitor Closely (1)lenacapavir will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lencapavir may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates.lenvatinibMonitor Closely (1)trazodone and lenvatinib both increase QTc interval. Use Caution/Monitor. Lenvatinib prescribing information recommends monitoring ECG closely when coadministered with QT prolonging drugs.leuprolideMonitor Closely (1)leuprolide increases toxicity of trazodone by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.levalbuterolMonitor Closely (1)trazodone increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)trazodone, levalbuterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.levofloxacinMonitor Closely (1)trazodone and levofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.levoketoconazoleSerious - Use Alternative (2)trazodone and levoketoconazole both increase QTc interval. Avoid or Use Alternate Drug. levoketoconazole will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.levomilnacipranSerious - Use Alternative (1)levomilnacipran and trazodone both increase serotonin levels. Avoid or Use Alternate Drug.levorphanolMonitor Closely (1)levorphanol and trazodone both increase sedation. Use Caution/Monitor.linagliptinMonitor Closely (1)trazodone will decrease the level or effect of linagliptin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Use of alternative treatments is strongly recommended when linagliptin is to be administered with a P-gp inducer.linezolidSerious - Use Alternative (1)linezolid and trazodone both increase serotonin levels. Avoid or Use Alternate Drug. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first.lisdexamfetamineMonitor Closely (1)trazodone increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)trazodone, lisdexamfetamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.lithiumMonitor Closely (1)trazodone and lithium both increase serotonin levels. Modify Therapy/Monitor Closely.Serious - Use Alternative (1)lithium and trazodone both increase QTc interval. Avoid or Use Alternate Drug.Minor (2)lithium, trazodone. Other (see comment). Minor/Significance Unknown. Comment: Risk of neurotoxicity in geriatric pts. Multiple mechanisms involved. trazodone, lithium. Mechanism: unknown. Minor/Significance Unknown. Risk of neurotoxicity.lofepramineMonitor Closely (2)lofepramine and trazodone both decrease cholinergic effects/transmission.